Maria Cristina Da Mosto

Maria Cristina Da Mosto

Auto-generated profile, based on publicly available information

Maria Cristina Da Mosto

ENT Clinic, Department of Neurosciences, Treviso Regional Hospital, University of Padua, Treviso, Italy

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2009 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
APAgostino Paccagnella
Agostino Paccagnella
MMMichela Morello
Michela Morello
MMMaria C. Da Mosto
Maria C. Da Mosto
CBCarla Baruffi
Carla Baruffi
MMMaria L. Marcon
Maria L. Marcon
CMCarlo Marchiori
Carlo Marchiori

16 November 2004 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
PDF file
PZPier Luigi Zorat
Pier Luigi Zorat
APAdriano Paccagnella
Adriano Paccagnella
GCGiancarlo Cavaniglia
Giancarlo Cavaniglia
LLLucio Loreggian
Lucio Loreggian
AGAlessandro Gava
Alessandro Gava
MGMaria Grazia Ghi
Maria Grazia Ghi
In 1986, we initiated a multicenter, randomized trial to compare induction chemotherapy with cisplatin and 5-fluorouracil followed by locoregional treatment (surgery and radiotherapy or radiotherapy alone) with locoregional treatment alone in patients with head and neck squamous cell carcinoma. Here we report the long-term results of the trial. A total of 237 patients with nonmetastatic stage III or IV head and neck carcinoma were randomly assigned to receive four cycles of neoadjuvant chemotherapy followed by locoregional treatment (group A) or locoregional treatment alone (group B). Among all patients, overall survival at 5 and 10 years was 23% (95% confidence interval [CI] = 15.3% to 30.9%) and 19% (95% CI = 11.6% to 26.4%), respectively, for those in group A and 16% (95% CI = 9.6% to 23.4%) and 9% (95% CI = 3.5% to 14.7%), respectively, for those in group B (P = .13). Among operable patients, we observed no difference between group A and group B in overall survival at 5 and 10 years (group A, 31% [95% CI = 14.9% to 47.3%] and 22.7% [95% CI = 7.1% to 38.3%], respectively; group B, 43.3% [95% CI = 25.6% to 61.0%] and 14.2% [95% CI = 0.1% to 28.3%], respectively; P = .73). Among inoperable patients, overall survival at 5 and 10 years was 21% (95% CI = 12.3% to 30.1%) and 16% (95% CI = 7.7% to 23.9%), respectively, for group A and 8% (95% CI = 1.5% to 12.3%) and 6% (95% CI = 0.1% to 9.1%), respectively, for group B (log-rank P = .04). Four cycles of neoadjuvant chemotherapy is a promising approach for treating patients with inoperable advanced head and neck cancer but not for treating patients with operable disease.

14 September 2011 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
PBPaolo Boscolo-Rizzo
Paolo Boscolo-Rizzo
MSMarco Stellin
Marco Stellin
EMEnrico Muzzi
Enrico Muzzi
MMMonica Mantovani
Monica Mantovani
RFRoberto Fuson
Roberto Fuson
MMMaria Cristina Da Mosto
Maria Cristina Da Mosto

1 February 2008 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
PBPaolo Boscolo-Rizzo
Paolo Boscolo-Rizzo
FMFrancesca Maronato
Francesca Maronato
CMCarlo Marchiori
Carlo Marchiori
AGAlessandro Gava
Alessandro Gava
MMMaria Cristina Da Mosto
Maria Cristina Da Mosto

1 May 2009 in International Journal of Infectious Diseases
Verified
Journal Article
Closed access
PBPaolo Boscolo-Rizzo
Paolo Boscolo-Rizzo
MMMaria Cristina Da Mosto
Maria Cristina Da Mosto

5 February 2008 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
PBPaolo Boscolo-Rizzo
Paolo Boscolo-Rizzo
GCGiuseppe De Cillis
Giuseppe De Cillis
CMCarlo Marchiori
Carlo Marchiori
SCSilvia Carpenè
Silvia Carpenè
MMMaria Cristina Da Mosto
Maria Cristina Da Mosto